

CLAIMS

- 125 B1
1. Use of a soluble form of a receptor for a growth factor in the manufacture of a medicament for enhancing the intracerebral, extracerebral, intraparenchymal, intracerebraventricular or intrathecal delivery of said growth factor by coadministration of said growth factor with said soluble form of the growth factor receptor.
 2. Use according to claim 1 wherein the growth factor is a neurotrophin.
 3. Use according to claim 1 wherein the growth factor is Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin 3 (NT-3), Neurotrophin- 4/5 (NT-4/5), Ciliary Neurotrophic Factor (CNTF) or Glial-Derived Neurotrophic Factor (GDNF).
 - 125 A
 4. Use according to any one of the preceding claims wherein said soluble receptor is in the form of a receptorbody.
 5. Use according to any one of the preceding claims wherein said growth factor is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.
 - 125 B2
 6. Use according to claim 5 wherein said growth factor is BDNF and the soluble receptor is a TrkBIGG receptorbody.
 7. A pharmaceutical composition comprising a growth factor; a soluble form of a receptor for said growth factor; and a pharmaceutically acceptable vehicle.
 8. A pharmaceutical composition according to claim 7 wherein the growth factor is a neurotrophin.
 9. A pharmaceutical composition according to claim 7 wherein the growth factor is Nerve Growth Factor (NGF), Brain-

Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5), Ciliary Neurotrophic Factor (CNTF) or Glial-Derived Neurotrophic Factor (GDNF).

- 125 A2
10. A pharmaceutical composition according to any one of claims 7 to 9 wherein said soluble receptor is in the form of a receptorbody.
11. A pharmaceutical composition according to any one of claims 7 to 10 said growth factor is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.
- 125 B3
12. A pharmaceutical composition according to claim 11 wherein said growth factor is BDNF and the soluble receptor is a TrkB IgG receptorbody.
13. A method for enhancing the intracerebral, extracerebral, intraparenchymal, intracerebraventricular or intrathecal delivery of a growth factor by coadministration of said growth factor with said soluble form of the growth factor receptor.
14. A method according to claim 13 wherein the growth factor is a neurotrophin.
15. A method according to claim 13 wherein the growth factor is Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5), Ciliary Neurotrophic Factor (CNTF) or Glial-Derived Neurotrophic Factor (GDNF).
- 125 B3
16. A method according to any one of claims 13 to 15 wherein said soluble receptor is in the form of a receptorbody.
17. A method according to claim 13 to 16 said growth factor

A3 wsf

is BDNF or NT-3 and the soluble receptor is the extracellular domain of TrkB or TrkC.

125
B4

18. A method according to claim 17 wherein said growth factor is BDNF and the soluble receptor is a TrkB1gG receptorbody.
19. Use according to claim 1 substantially as hereinbefore described.
20. A pharmaceutical composition according to claim 7 substantially as hereinbefore described.
21. A method according to claim 13 substantially as hereinbefore described.